Jazz Pharmaceuticals Plc JAZZ,
said on Wednesday he had agreed to acquire GW Pharmaceuticals Plc GWPH,
in a $ 7.2 billion cash-and-stock transaction. Under the agreement, Jazz Pharma will pay $ 200 per share in cash and $ 20 per share for each share held, or a premium of approximately 50% on GW’s closing price on Tuesday and 60% above its 30-day weighted average. average. price. The transaction is expected to end in the second quarter, to increase profits in the first year afterward and to increase double-digit revenue growth. GW is a leader in therapies based on its own cannabinoid product platform to treat a number of diseases. The company was the first to receive FDA approval for a downtown-based treatment for severe forms of childhood epilepsy in its Epidiolex lead product. Jazz makes sleep medicine and has a growing oncology business. GW Pharma shares rose the pre-market by 46% after trading resumed after the news stopped. Jazz shares rose 2.7%, but rose 11% over the past 12 months, while the S&P 500 SPX,
achieved 18%.
